RxDoctor Payments Data

Martin Baumohl

Optometrist · Spring, TXNPI 1629071865

Payments from drug & device makers

$37,437in general payments, 2019–2025

Across 399 payments — averaging $93.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$28K
  • AbbVie$2K
  • Sun Pharmaceutical Industries Inc.$2K
  • Biotissue Holdings Inc.$975
  • Oyster Point Pharma, Inc.$747
  • Tarsus Pharmaceuticals, Inc.$707
  • plus $3K from 16 others

What the payments were for

  • Consulting fees$8,38022%
  • Speaking & faculty fees$12,69534%
  • Travel & lodging$4,26411%
  • Food & beverage$12,07932%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,437 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$70,066
Medicare patients
317
Services billed
804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine61$61,172
LumiganBimatoprost60$34,019
XiidraLifitegrast22$32,371
XdemvyLotilaner13$23,563
Cyclosporine18$11,614
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$4,577
Latanoprost364$4,370
Brimonidine Tartrate52$4,170
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat192$2,813
Tobramycin-DexamethasoneTobramycin/Dexamethasone29$1,021
Timolol Maleate43$524
Prednisolone Acetate13$524
Dorzolamide Hcl14$410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$2,355$95,191121 claims
Bausch & Lomb Americas Inc.Xiidra$334$32,37122 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$707$23,56313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.

Other optometrist in Spring

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →